A retrospective study of endoscopic and histologic outcomes and impact of these anti-TNF exposure in pediatric patients treated with vedolizumab
Latest Information Update: 13 Jul 2021
Price :
$35 *
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Therapeutic Use
- 13 Jul 2021 New trial record